Amgen's Bradway nets $13.65M in 2013, sans Onyx bonus

Amgen CEO Robert Bradway

Amgen ($AMGN) CEO Robert Bradway may have orchestrated 2013's biggest M&A deal in pharma, nabbing Onyx Pharmaceuticals for $10.4 billion last summer, but that wasn't enough to net him the kind of deal-related bonus some of his peers enjoy. But it's not as though the helmsman went empty-handed in 2013: His take-home increased over last year's haul, which was enough to score him 13th place on the list of biopharma's highest-paid chiefs.

According to a proxy filing, Bradway made $13.65 million in total compensation for 2013, an improvement on the $13.57 million he pocketed for his work in 2012. About $1.5 million of that came from his base salary, with stock units--performance-based and restricted--tallying about $8 million, incentive plan compensation totaling close to $3.6 million and other compensation coming in at $561,121.

But as far as bonuses go, Bradway's was nil--as were those of Amgen's EVPs. To put things in context, Actavis ($ACT) CEO Paul Bisaro recently netted a $4 million bonus from his company's compensation committee, which gave "special consideration for the completion of the acquisition of Warner Chilcott"--an $8.5 billion pickup.

It's not as if the Onyx acquisition didn't factor into Bradway's pay at all. Take his nonequity incentives, for instance: Amgen based his annual cash award payments on the company's financial and operational performance against its targets, with revenue and adjusted net income each weighted 30%. And Kyprolis, Onyx's star blood cancer product, brought in $73 million in 2013 after the deal's completion, helping revenues surpass their $18 billion target and, in turn, helping Bradway's cash awards toward that $3.6 million mark.

Still, it's a relatively small impact compared with the effect Onyx and Kyprolis will have on Amgen's top line, especially considering Bradway's role in bagging the California-based biotech. In an unconventional M&A move applauded by analysts, he asked Onyx for trial data on the multiple myeloma med--a potential $3-billion-a-year seller, some say--that he knew the company couldn't provide, using its refusal as grounds to shave down his bidding price.

- read the proxy (PDF)

Special Report: 20 Highest-Paid Biopharma CEOs of 2012 - Robert Bradway - Amgen

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.